Ashwani Verma
Stock Analyst at UBS
(4.54)
# 1,033
Out of 4,698 analysts
230
Total ratings
62.4%
Success rate
13.5%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintained: Buy | $42 → $48 | $36.62 | +31.08% | 31 | Sep 4, 2026 | |
| ASMB Assembly Biosciences | Initiated Coverage: Buy | $52 | $36.13 | +43.92% | 1 | Sep 1, 2026 | |
| ALVO Alvotech | Rated: Buy | $6 | $5.38 | +11.52% | 4 | Aug 24, 2026 | |
| ACAD ACADIA Pharmaceuticals | Rated: Buy | $40 → $49 | $27.86 | +75.88% | 11 | Aug 18, 2026 | |
| LEGN Legend Biotech | Rated: Hold | $28 | $21.75 | +28.74% | 10 | Aug 13, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Buy | $315 | $247.57 | +27.24% | 17 | Aug 11, 2026 | |
| RPRX Royalty Pharma | Maintained: Buy | $57 → $66 | $63.88 | +3.32% | 12 | Aug 11, 2026 | |
| MPLT MapLight Therapeutics | Downgraded: Hold | $52 → $13 | $13.14 | -1.07% | 3 | Aug 11, 2026 | |
| INSM Insmed | Maintained: Buy | $166 → $172 | $126.68 | +35.78% | 8 | Aug 7, 2026 | |
| VTRS Viatris | Maintained: Buy | $23 | $16.94 | +35.77% | 7 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $23 → $25 | $17.87 | +39.90% | 4 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $208 → $231 | $158.35 | +45.88% | 19 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $113 | $128.00 | -11.72% | 13 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $669 | $542.61 | +23.29% | 1 | Jul 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $40 → $52 | $59.13 | -12.06% | 9 | Jul 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $69 → $115 | $73.95 | +55.51% | 13 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 | $15.86 | -30.64% | 6 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $95 → $72 | $112.80 | -36.17% | 2 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $42 → $48 | $46.88 | +2.39% | 7 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $251 → $259 | $208.35 | +24.31% | 12 | Apr 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $645 → $705 | $490.24 | +43.81% | 19 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1,080 | $1,159.60 | -6.86% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $220 | $260.21 | -15.45% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 → $43 | $41.86 | +2.72% | 5 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $18 | $39.12 | n/a | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.05 → $1.1 | $1.37 | n/a | 7 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $119 → $130 | $224.51 | n/a | 4 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $3.79 | n/a | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 | $0.8522 | n/a | 1 | Oct 11, 2022 |
Teva Pharmaceutical Industries
Sep 4, 2026
Maintained: Buy
Price Target: $42 → $48
Current: $36.62
Upside: +31.08%
Assembly Biosciences
Sep 1, 2026
Initiated Coverage: Buy
Price Target: $52
Current: $36.13
Upside: +43.92%
Alvotech
Aug 24, 2026
Rated: Buy
Price Target: $6
Current: $5.38
Upside: +11.52%
ACADIA Pharmaceuticals
Aug 18, 2026
Rated: Buy
Price Target: $40 → $49
Current: $27.86
Upside: +75.88%
Legend Biotech
Aug 13, 2026
Rated: Hold
Price Target: $28
Current: $21.75
Upside: +28.74%
Jazz Pharmaceuticals
Aug 11, 2026
Reiterated: Buy
Price Target: $315
Current: $247.57
Upside: +27.24%
Royalty Pharma
Aug 11, 2026
Maintained: Buy
Price Target: $57 → $66
Current: $63.88
Upside: +3.32%
MapLight Therapeutics
Aug 11, 2026
Downgraded: Hold
Price Target: $52 → $13
Current: $13.14
Upside: -1.07%
Insmed
Aug 7, 2026
Maintained: Buy
Price Target: $166 → $172
Current: $126.68
Upside: +35.78%
Viatris
Aug 7, 2026
Maintained: Buy
Price Target: $23
Current: $16.94
Upside: +35.77%
Aug 3, 2026
Maintained: Buy
Price Target: $23 → $25
Current: $17.87
Upside: +39.90%
Jul 31, 2026
Maintained: Buy
Price Target: $208 → $231
Current: $158.35
Upside: +45.88%
Jul 28, 2026
Maintained: Hold
Price Target: $113
Current: $128.00
Upside: -11.72%
Jul 21, 2026
Maintained: Buy
Price Target: $669
Current: $542.61
Upside: +23.29%
Jul 2, 2026
Rated: Hold
Price Target: $40 → $52
Current: $59.13
Upside: -12.06%
Jun 29, 2026
Upgraded: Buy
Price Target: $69 → $115
Current: $73.95
Upside: +55.51%
May 28, 2026
Reiterated: Hold
Price Target: $11
Current: $15.86
Upside: -30.64%
May 13, 2026
Upgraded: Buy
Price Target: $95 → $72
Current: $112.80
Upside: -36.17%
May 6, 2026
Maintained: Buy
Price Target: $42 → $48
Current: $46.88
Upside: +2.39%
Apr 10, 2026
Rated: Buy
Price Target: $251 → $259
Current: $208.35
Upside: +24.31%
Mar 5, 2026
Rated: Buy
Price Target: $645 → $705
Current: $490.24
Upside: +43.81%
Nov 7, 2025
Maintained: Buy
Price Target: $1,080
Current: $1,159.60
Upside: -6.86%
Nov 7, 2025
Maintained: Hold
Price Target: $220
Current: $260.21
Upside: -15.45%
Oct 14, 2025
Maintained: Buy
Price Target: $50 → $43
Current: $41.86
Upside: +2.72%
Jul 29, 2025
Maintained: Hold
Price Target: $18
Current: $39.12
Upside: n/a
Jul 21, 2025
Maintained: Hold
Price Target: $1.05 → $1.1
Current: $1.37
Upside: n/a
Jul 14, 2025
Maintained: Hold
Price Target: $119 → $130
Current: $224.51
Upside: n/a
Jun 17, 2025
Maintained: Buy
Price Target: $5
Current: $3.79
Upside: n/a
Oct 11, 2022
Initiated Coverage: Buy
Price Target: $15
Current: $0.8522
Upside: n/a